
    
      The purpose of this study is to evaluate the activity and safety of PD0332991 in patients
      with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET)
      with overexpression of cell cycle markers (Cdk4 and/or phospho-Rb1 and/or cyclin D1)
    
  